Login to Your Account



Clinic Roundup


Friday, April 6, 2012
• Molecular Partners AG, of Schlieren, Switzerland, said partner Allergan Inc., of Irvine, Calif., recently reported that AGN-150998/MP0112, an anti-VEGF DARPin compound, was shown to be safe and well tolerated, with no dose-limiting toxicity, after a single administration in Phase IIa trial in macular edema. Preliminary efficacy results suggested a dosing interval of up to three months.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription